Nutrient compositions

Abstract: A nutrient composition includes at least two oligopep­ tides of amino acids having in the N-terminal position of at least one oligopeptide a residue of glycine and having in the N-terminal position of at least one oligopeptide a residue of L-alanine, L-lysine or L-arginine. The aqueous composi­ tions may also contain free amino acids and may contain other nutrient substances such as fats, oligosaccharides, minerals, trace elements, vitamins and free amino acids. The compositions are intended for oral or parenteral use with mammals. Compositions having dipeptide concentra­ tions higher than prior art compositions are disclosed. Com­ positions containing elevated concentrations of total protein greater than heretofor proposed employ both the described oligopeptides and also free amino acids.

Description: Description of the Prior Art - U.S. Patent 4,340,592 and DE-A 3108079 describes nutrient compositions of dipeptides and tripeptides and the method of administering the compositions to mammals for dietary purposes. The important developments described in U.S. Patent 4,340,592 provide a composition which can be employed to supplement nutritional deficiencies or to provide a complete nutritional composition, particularly for a comatose patient or a patient having metabolic or digestive interference. The introduction of large quantities of free amino acids into a mammal tends to establish hypertonicity and metabolic interference. The expression "protein nutrients" herein includes free amino acids, organic acid amides of amino acids and oligopeptides. The nutritional problems arising from using free amino acids could be avoided by employing an aqueous mixture containing oligopeptides, that is, dipeptides or tripeptides, of the essential amino acids and other amino acids wherein the N-terminal amino acid is a glycine residue. The glycine terminal amino acid residue achieves water solubility and achieves excellent absorption of the oligopeptides. While the use of the described aqueous solution of glycine-terminated dipeptides and tripeptides achieves the objectives set forth, there are some improvements which are useful, particularly in providing a complete nutritional composition. (1) There may be a tendency to develop excess glycine in the patient as a result of using glycine as the N-terminal amino acid residue in all of the oligopeptides. There is no evidence that excess glycine creates any medical problems. (2) Free amino acids are limitedly soluble in water. Glycine terminated oligopeptides are highly soluble in water. However nutrient compositions containing glycine oligopeptides and/or free amino acids heretofore have been employed in concentrations of 20 weight percent peptide or less, usually less than 15 weight percent total protein content, i.e., the sum of the weight of oligopeptides and the weight of free amino acids. The use of such relatively low concentration aqueous nutrient compositions interferes with development of a complete nutrition system because of the water-intake limits for parenteral nutrition. There is an established limit for the amount of water which can be introduced parenterally into a patient. Approaching that water-intake limit will cause serious problems in medical patients having heart deficiencies or kidney deficiencies. Achieving and exceeding the water-intake limit may be fatal for such patients. Therefore such medical patients cannot be maintained parenterally for extended periods solely by prior art nutrient compositions. Such medical patients heretofore are effectively starving during those periods when they are unable to absorb nutrition except parenterally. It is possible to introduce maintenance-quantities of oligosaccharides, fats, minerals, trace elements and vitamins but it is not possible to introduce sufficient protein ingredients parenterally in the form of free amino acids. STATEMENT OF THE PRESENT INVENTION It is to state that the new aqueous nutrient compositions can be employed in higher concentrations --- up to about 40 weight percent total protein, i.e., the sum of the oligopeptides and the free amino acids --- a much higher range than was heretofore believed to be possible. The higher concentrations are achieved by combining free amino acids, as desired, with oligopeptides, as desired, to provide the proportions of total protein nutrients which are appropriate to the needs of the patient. The potential glycine excess can be avoided by providing at least some of the oligopeptides as glycine-terminated oligopeptides and providing other oligopeptides which are terminated with alanine or arginine or lysine moieties. The concentration of the oligopeptides is from 2 to 20 weight percent. The total protein content consisting of free amino acids and oligopeptides is from 10 to 40 weight percent. The high concentrations of protein ingredients permit reduced fluid loads for the patient. Nutrient compositions having lower concentrations of protein ingredients are useful, particularly with certain essential amino acids such as tryptophan and tyrosine which are difficult to provide as parenteral nutrients. According to the present invention, novel nutritional compositions are prepared which are aqueous solutions containing at least one oligopeptide consisting of a dipeptide or a tripeptide wherein the N-terminal amino acid residue is glycine residue, and at least one oligopeptide consisting of a dipeptide or a tripeptide wherein the N-terminal amino acid residue is selected from the class consisting of alanine, lysine and arginine. The oligopeptide concentration is from 2 to 20 weight percent. For total parenteral nutrition, the preferred range is from 5 to 15 weight percent of the oligopeptide. The total protein nutrients in the compositions are from 10 to 40 weight percent. The free amino acids are preferably those which can be supplied as aqueous solute and which have stability in storage. The oligopeptides preferably include amino acid moieties which are difficultly soluble in water and those which are unstable in the free amino acid state. In order to develop a complete nutritional composition, the compositions also may contain other nutrient ingredients such as oligosaccharides, fats, minerals, trace elements, vitamins and free amino acids. The oligopeptides comprise from about 2 to 20 weight percent of the aqueous solution, preferably from 5 to 15 weight percent. The composition also may include free amino acids for the reasons already set forth. The composition is intended for oral, gastrointestinal or intravenous introduction into a patient. DESCRIPTION OF THE PREFERRED EMBODIMENTS The composition set forth in Table I has been prepared as a nutrient composition which has been effective to maintain a laboratory animal as a complete nutritional source for an extended period of time. Aqueous Nutrient Composition of Investigation 1 Dipeptide Concentration (millimoles/liter) Gly-L-Thr 10.8 Gly-L-Val 16.3 Gly-L-Met 7.6 Gly-L-Ile 12.9 Gly-L-Leu 18.8 Lys-L-Lys 5.0 Gly-L-Trp 3.0 Gly-L-His 6.0 Gly-L-Phe 7.6 Arg-L-Glu 12.6 Gly-L-Pro 6.0 Gly-L-Ala 15.0 Gly-L-Tyr 6.0 Gly-L-Gln 30.0 Ala-L-Ala 39.3 The conventional abbreviations of Table I are: Ala Alanine Lys Lysine Arg Arginine Met Methionine Gln Glutamine Phe Phenylalanine Glu Glutamic acid Pro Proline Gly Glycine Thr Threonine His Histidine Trp Tryptophan Ile Isoleucine Tyr Tyrosine Leu Leucine Val Valine The Table 1 composition contains all of the essential amino acids and also includes some of the non-essential amino acids. It is well known that the essential amino acids include lysine, leucine, isoleucine, tryptophan, methionine, valine, phenylalanine, threonine. Non-essential amino acids induce arginine, histidine, alanine, proline, glycine, glutamic acid, asparagine, aspartate, cysteine, glutamine, serine, taurine, hydroxyproline, citrulline, alpha-amino-n-butyric acid, cystathionine and ornithine. It will be observed from Table I that most of the dipeptides in the nutrient composition have a glycine residue in the N-terminal position. However the Lys-L-Lys (Lysyl lysine), the Arg-L-Glu (Arginyl-glutamic acid) and the Ala-L-Ala (Alanyl-alanine) contain lysine, arginine and alanine, respectively as the N-terminal amino acid residue. The composition of Table I has been specially prepared to supply, as peptides, appropriate quantities of the essential amino acids and appropriate quantities of some important non-essential amino acids. By employing some dipeptides which are terminated with the lysine, alanine, arginine residues, the tendency for the patient to develop glycine excess is avoided, in a preferred nutrient composition, the dipeptide formulation of Table I is combined with life-maintenance quantities of oligosaccharides, fats, minerals, vitamins and free amino acids as an aqueous mixture which functions as a complete nutrient composition, particularly for a patient who is comatose or afflicted with gastro-intestinal problems resulting from illness, injury or surgery. The nutrient compositions of this invention may be administered as described in the aforementioned U.S. Patent 4,340,592, e.g., orally, intragastrointestinally and intravenously. Additional investigations were carried out with a peptide composition according to the invention set forth in Table 2. Aqueous Nutrient Composition of Investigation 2 --- Protein Nutrient Content 20 Weight Percent Substance Concentration millimoles per liter grams per liter glycyl-L-isoleucine 74.37 14.0 L-isoleucine 38.12 5.0 glycyl-L-leucine 85.00 16.0 L-leucine 41.93 5.5 glycyl-L-valine 137.76 24.0 L-valine 68.29 8.0 glycyl-L-tyrosine 31.46 7.5 glycyl-L-glutamine 44.29 9.0 L-alanyl-L-glutamine 20.72 4.5 L-lysine-L-glutamate 37.50 11.0 L-lysine 41.04 6.0 L-ornithine-L-aspartate 28.27 7.5 L-arginine 52.81 9.2 L-histidine 59.29 9.2 L-serine 87.54 9.2 L-threonine 77.23 9.2 L-alanine 207.66 18.5 L-proline 79.91 9.2 N-acetyl-L-cysteine 3.06 0.5 L-methionine 50.26 7.5 L-phenylalanine 33.29 5.5 L-tryptophan 19.59 4.0 Total 200.00 It will be observed that the composition of Table 2 includes several free amino acids, one organic acid amide of an amino acid and also includes glycine-terminated dipeptides and includes alanine-terminated dipeptides. The total glycine concentration in this composition was 14 weight percent. Laboratory animal investigations were carried out with the nutrient composition of Table 2. Effective nutrition was achieved with the laboratory animals over extended periods. The glycine content of the laboratory animal plasma after this investigation was 736. The laboratory animals exhibited no ill effects which might be associated with nutrition. The urinary excretion of dipeptides during the investigation was less than 1 percent of the amount of infused peptides, which suggests conversion and utilization of the parenterally introduced peptides. The tests established firm evidence for efficacy and safety of a dipeptide mixture as described as the sole nitrogen source for parenteral nutrition in mammals. A typical nutrient composition for parenteral nutrition having a higher concentration of protein solute than previously contemplated is set forth in Table 4. Aqueous Nutrient Composition of Investigation 3 --- Protein Nutrient Content 40 Weight Percent Substance Concentration grams per liter millimoles per liter glycyl-L-isoleucine 16.1 85.54 glycyl-L-leucine 21.9 116.08 glycyl-L-valine 18.3 104.90 L-alanyl-L-tyrosine 17.6 69.76 glycyl-L-glutamine 35.5 174.92 L-glutamic acid 33.0 224.56 L-lysine 18.0 123.06 L-arginine 37.4 214.70 L-histidine 9.4 60.26 L-serine 37.4 355.90 L-threonine 14.4 121.10 L-alanine 69.5 779.66 L-proline 37.4 324.86 N-acetyl-L-cysteine 0.8 4.90 L-methionine 14.4 96.68 L-phenylalanine 13.4 80.86 L-tryptophan 5.6 27.46 Total 400.0 In Table 4 the nutrient composition includes 11 weight percent peptides including glycine-terminated peptides and one alanyl-terminated peptide (Alanyl-tyrosine). Cysteine is presented as an amide of an organic acid. The total protein content (peptides and free amino acids) is 40 weight percent. Such concentrated, soluble total protein compositions are not proposed in the prior art. The composition of Table 3 contains all of the essential amino acids either as free amino acids or as moieties of an oligopeptide.

Claims: A parenteral nutrient composition comprising an aqueous solution containing from 10 to 40 weight percent of protein nutrients including 2 to 20 weight percent of oligopeptides consisting of dipeptides and tripeptides wherein at least one said oligopeptide contains a glycine residue as the N-terminal amino acid residue; and at least one said oligopeptide contains as the N-terminal amino acid residue an amino acid residue selected from the class consisting of alanine, lysine and arginine. The nutrient composition of Claim 1 including alanyl tyrosine as one of the said oligopeptides. The nutrient composition of Claim 1 including arginyl glutamic acid as one of the said oligopeptides. The nutrient composition of Claim 1 including lysyl lysine as one of the said oligopeptides. The nutrient composition of Claim 1 including other nutrients selected from the class consisting of fats, oligosaccharides, minerals, trace elements, vitamins and free amino acids. The nutrient composition of Claim 1 containing all essential amino acids, either as free amino acids or as amino acid residues in the said oligopeptides. The nutrient composition of Claim 1 containing at least one non-essential free amino acid. The nutrient composition of claim 1 comprising dipeptides of L-threonine, L-valine, L-methionine, L-isoleucine, L-leucine, L-lysine, L-tryptophan, L-histidine, L-phenylalanine, L-glutamic acid, L-proline, L-glutamine, L-alanine and L-tyrosine, and, as the N-terminal residue of at least one of said dipeptides, a glycine residue and, as the N-terminal residue of at least one of said dipeptides, at least one other amino acid residue selected from the class consisting of L-alanine, L-lysine and L-arginine. The parenteral nutrient composition of Claim 1 including an organic acid amide of an amino acid.

Inventors: ADIBI SIAMAK A, BRANDL MARIA, FEKL WERNER, LANGER KLAUS, ADIBI, SIAMAK A., BRANDL, MARIA, FEKL, WERNER, LANGER, KLAUS
Applicants: MONTEFIORE HOSPITAL ASS OF WES, PHARMACIA & UPJOHN GMBH, THE MONTEFIORE HOSPITAL ASSOCIATION OF WESTERN PENNSYLVANIA
Application year: 1985
Main classification: A23L1
IPC codes: A23L1, C07K5